98547-86-5Relevant academic research and scientific papers
Photo- and electro-luminescence of three TADF binuclear Cu(i) complexes with functional tetraimine ligands
Lin, Ling,Chen, Dong-Hui,Yu, Rongmin,Chen, Xu-Lin,Zhu, Wen-Juan,Liang, Dong,Chang, Jian-Fei,Zhang, Qing,Lu, Can-Zhong
, p. 4495 - 4504 (2017)
Three new binuclear cuprous complexes with similar tetraimine ligands [Cu2(pytzph)(POP)2](BF4)2 (1), [Cu2(pytzphcf)(POP)2](BF4)2 (2) and [Cu2(pytzphcz)(POP)2](BF4)2 (3), (pytzph = 6,6′-(1-phenyl-1,2,4-triazole-3,5-diyl)bis(2-methylpyridine), pytzphcf = 6,6′-(1-(4-(trifluoromethyl)phenyl)-1,2,4-triazole-3,5-diyl)bis(2-methylpyridine), pytzphcz = 9-(4-(3,5-bis(6-methylpyridin-2-yl)-1,2,4-triazol-1-yl)phenyl)-carbazole and POP = bis[2-(diphenylphosphine)phenyl]ether), have been synthesized and characterized in order to compare the different effects of substituent groups on the photoluminescence (PL) and electroluminescence (EL) properties. These complexes exhibit highly efficient green thermally activated delayed fluorescence (TADF) with short decay times (5.5-16 μs) and high photoluminescence quantum yields (up to 79%) at room temperature in the solid form. These complexes have essentially identical emission energy. However, the influence of the substituents on the photoluminescence and electroluminescence efficiencies is evident. Complex 3 with the carbazole group shows the highest efficiency in terms of both PL and EL, exhibiting an EQE of 8.3%, a CE of 27.1 cd A-1 and a peak brightness of 2525 cd cm-2 in the solution-processed OLED, while complex 2 with a trifluoromethyl appendage exhibits poorer quantum efficiency than the others.
TRIAZOLE AGONISTS OF THE APJ RECEPTOR
-
Paragraph 0350, (2016/12/07)
Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.
P2X7 MODULATORS
-
Paragraph 0214, (2014/09/29)
The present invention is directed to a compound of Formula (I): The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invent
P2X7 MODULATORS
-
Paragraph 0126; 0166; 0177, (2014/09/30)
The present invention is directed to a compound of Formula (I) and to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
-
Page/Page column 118-119, (2013/04/24)
The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS
-
Page/Page column 101, (2011/10/13)
The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.
COMPOUNDS AND METHODS FOR TREATING LEUKEMIA
-
Page/Page column 37-38; 1/13, (2009/01/23)
Compounds hat are inhibitors of transcription factors of leukemia cell lines are provided. In addition, pharmaceutical compositions including the inhibiting compounds and methods for treating leukemia are also provided.
Self-assembled polymetallic square grids ([2 × 2] M4, [3 × 3] M9) and trigonal bipyramidal clusters (M5) - Structural and magnetic properties
Dawe, Louise N.,Abedin, Tareque S. M.,Kelly, Timothy L.,Thompson, Laurence K.,Miller, David O.,Zhao, Liang,Wilson, Claire,Leech, Michael A.,Howard, Judith A. K.
, p. 2645 - 2659 (2007/10/03)
New self-assembled grids and clusters are reported, with square [2 × 2] M4 (M = Mn(ii)4, Cu(ii)4), trigonal-bipyramidal Mn(ii)5, and square [3 × 3] M9 (M = Mn(ii), Cu(ii)) examples. These are based on a series of ditopic and tritopic hydrazone ligands involving pyridine, pyrimidine and imidazole end groups. In all cases the metal centres are bridged by hydrazone oxygen atoms with large (>125°) bridge angles, leading to antiferromagnetic exchange for all the Mn systems (J = -2 to -5 cm-1), which results in S = 0 (Mn4), and S = 5/2 (Mn5, Mn9) ground states. The copper systems have a 90° alternation of the Jahn-Teller axes within the Cu4 and Cu8 grid rings (Cu9), which leads to magnetic orbital orthogonality, and dominant ferromagnetic coupling. For the Cu9 grid antiferromagnetic exchange between the ring and the central copper leads to a S = 7/2 ground state, while for the Cu4 grids S = 4/2 ground states are observed. The magnetic data have been treated using isotropic exchange models in the cases of the Cu4 and Cu9 grids, and the Mn5 clusters. However due to the enormity of a fully isotropic calculation a simplified model is used for the Mn9 grid, in which the outer Mn8 ring is treated as the equivalent of an isolated magnetic chain, with no coupling to the central metal ion. The Royal Society of Chemistry 2006.
